Literature DB >> 28348034

What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Rigorous Simian Immunodeficiency Virus Vaccine Trials Can Be Instructive.

Mauricio A Martins1, David I Watkins1.   

Abstract

Simian immunodeficiency virus (SIV) challenge of rhesus macaques provides an invaluable tool to evaluate the clinical prospects of HIV-1 vaccine concepts. However, as with any animal model of human disease, it is crucial to understand the advantages and limitations of this system to maximize the translational value of SIV vaccine studies. Here, we discuss the importance of assessing the efficacy of vaccine prototypes using stringent SIV challenge regimens that mimic HIV-1 transmission and pathogenesis. We also review some of the cautionary tales of HIV-1 vaccine research because they provide general lessons for the preclinical assessment of vaccine candidates.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 28348034      PMCID： PMC5880168          DOI： 10.1101/cshperspect.a029504

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN： 1943-0264            Impact factor:   10.005


  59 in total

1.  Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses.

Authors:  K A Reimann; A Watson; P J Dailey; W Lin; C I Lord; T D Steenbeke; R A Parker; M K Axthelm; G B Karlsson
Journal:  Virology       Date:  1999-03-30       Impact factor: 3.616

2.  Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.

Authors:  Dan H Barouch; Galit Alter; Thomas Broge; Caitlyn Linde; Margaret E Ackerman; Eric P Brown; Erica N Borducchi; Kaitlin M Smith; Joseph P Nkolola; Jinyan Liu; Jennifer Shields; Lily Parenteau; James B Whitney; Peter Abbink; David M Ng'ang'a; Michael S Seaman; Christy L Lavine; James R Perry; Wenjun Li; Arnaud D Colantonio; Mark G Lewis; Bing Chen; Holger Wenschuh; Ulf Reimer; Michael Piatak; Jeffrey D Lifson; Scott A Handley; Herbert W Virgin; Marguerite Koutsoukos; Clarisse Lorin; Gerald Voss; Mo Weijtens; Maria G Pau; Hanneke Schuitemaker
Journal:  Science       Date:  2015-07-02       Impact factor: 47.728

3.  Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Authors:  Huma Qureshi; Zhong-Min Ma; Ying Huang; Gregory Hodge; Michael A Thomas; Janet DiPasquale; Veronique DeSilva; Linda Fritts; Andrew J Bett; Danilo R Casimiro; John W Shiver; Marjorie Robert-Guroff; Michael N Robertson; Michael B McChesney; Peter B Gilbert; Christopher J Miller
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

4.  Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Authors:  Peter B Gilbert; James O Berger; Donald Stablein; Stephen Becker; Max Essex; Scott M Hammer; Jerome H Kim; Victor G Degruttola
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

5.  Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

Authors:  D C Montefiori; K A Reimann; M S Wyand; K Manson; M G Lewis; R G Collman; J G Sodroski; D P Bolognesi; N L Letvin
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

7.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239.

Authors:  Mauricio A Martins; Nancy A Wilson; Shari M Piaskowski; Kim L Weisgrau; Jessica R Furlott; Myrna C Bonaldo; Marlon G Veloso de Santana; Richard A Rudersdorf; Eva G Rakasz; Karen D Keating; Maria J Chiuchiolo; Michael Piatak; David B Allison; Christopher L Parks; Ricardo Galler; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

9.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Authors:  David I Watkins; Dennis R Burton; Esper G Kallas; John P Moore; Wayne C Koff
Journal:  Nat Med       Date:  2008-06       Impact factor: 53.440

10.  Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.

Authors:  Michael Lopker; Juliet Easlick; Sarah Sterrett; Julie M Decker; Hannah Barbian; Gerald Learn; Brandon F Keele; James E Robinson; Hui Li; Beatrice H Hahn; George M Shaw; Katharine J Bar
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103
View more
  11 in total

1.  Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.

Authors:  Mauricio A Martins; Damien C Tully; Núria Pedreño-Lopez; Benjamin von Bredow; Matthias G Pauthner; Young C Shin; Maoli Yuan; Noemia S Lima; David J Bean; Lucas Gonzalez-Nieto; Aline Domingues; Martin J Gutman; Helen S Maxwell; Diogo M Magnani; Michael J Ricciardi; Varian K Bailey; John D Altman; Dennis R Burton; Keisuke Ejima; David B Allison; David T Evans; Eva G Rakasz; Christopher L Parks; Myrna C Bonaldo; Saverio Capuano; Jeffrey D Lifson; Ronald C Desrosiers; Todd M Allen; David I Watkins
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

Review 2.  Nonhuman Primates in Translational Research.

Authors:  Alice F Tarantal; Stephen C Noctor; Dennis J Hartigan-O'Connor
Journal:  Annu Rev Anim Biosci       Date:  2022-02-15       Impact factor: 13.341

3.  Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV Proteome.

Authors:  Mauricio A Martins; Lucas Gonzalez-Nieto; Michael J Ricciardi; Varian K Bailey; Christine M Dang; Georg F Bischof; Nuria Pedreño-Lopez; Matthias G Pauthner; Dennis R Burton; Christopher L Parks; Patricia Earl; Bernard Moss; Eva G Rakasz; Jeffrey D Lifson; Ronald C Desrosiers; David I Watkins
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

Review 4.  Antigen processing and presentation in HIV infection.

Authors:  Julie Boucau; Sylvie Le Gall
Journal:  Mol Immunol       Date:  2018-04-07       Impact factor: 4.407

5.  Recombinant Herpesvirus Vectors: Durable Immune Responses and Durable Protection against Simian Immunodeficiency Virus SIVmac239 Acquisition.

Authors:  Isabelle M Castro; Michael J Ricciardi; Lucas Gonzalez-Nieto; Eva G Rakasz; Jeffrey D Lifson; Ronald C Desrosiers; David I Watkins; Mauricio A Martins
Journal:  J Virol       Date:  2021-06-24       Impact factor: 5.103

6.  Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques.

Authors:  Mauricio A Martins; Young C Shin; Lucas Gonzalez-Nieto; Aline Domingues; Martin J Gutman; Helen S Maxwell; Iris Castro; Diogo M Magnani; Michael Ricciardi; Nuria Pedreño-Lopez; Varian Bailey; Dillon Betancourt; John D Altman; Matthias Pauthner; Dennis R Burton; Benjamin von Bredow; David T Evans; Maoli Yuan; Christopher L Parks; Keisuke Ejima; David B Allison; Eva Rakasz; Glen N Barber; Saverio Capuano; Jeffrey D Lifson; Ronald C Desrosiers; David I Watkins
Journal:  PLoS Pathog       Date:  2017-07-21       Impact factor: 6.823

7.  Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics.

Authors:  Sajjad Ahmad; Afifa Navid; Rabia Farid; Ghulam Abbas; Faisal Ahmad; Naila Zaman; Nousheen Parvaiz; Syed Sikander Azam
Journal:  Eur J Pharm Sci       Date:  2020-05-23       Impact factor: 4.384

8.  Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.

Authors:  Matthias G Pauthner; Joseph P Nkolola; Colin Havenar-Daughton; Ben Murrell; Samantha M Reiss; Raiza Bastidas; Jérémie Prévost; Rebecca Nedellec; Benjamin von Bredow; Peter Abbink; Christopher A Cottrell; Daniel W Kulp; Talar Tokatlian; Bartek Nogal; Matteo Bianchi; Hui Li; Jeong Hyun Lee; Salvatore T Butera; David T Evans; Lars Hangartner; Andrés Finzi; Ian A Wilson; Richard T Wyatt; Darrell J Irvine; William R Schief; Andrew B Ward; Rogier W Sanders; Shane Crotty; George M Shaw; Dan H Barouch; Dennis R Burton
Journal:  Immunity       Date:  2018-12-11       Impact factor: 31.745

9.  Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques.

Authors:  Lucas Gonzalez-Nieto; Isabelle M Castro; Georg F Bischof; Young C Shin; Michael J Ricciardi; Varian K Bailey; Christine M Dang; Nuria Pedreño-Lopez; Diogo M Magnani; Keisuke Ejima; David B Allison; Hwi Min Gil; David T Evans; Eva G Rakasz; Jeffrey D Lifson; Ronald C Desrosiers; Mauricio A Martins
Journal:  PLoS Pathog       Date:  2019-09-30       Impact factor: 6.823

10.  Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.

Authors:  Fredrik Barrenäs; Scott G Hansen; Lynn Law; Connor Driscoll; Richard R Green; Elise Smith; Jean Chang; Inah Golez; Taryn Urion; Xinxia Peng; Leanne Whitmore; Daniel Newhouse; Colette M Hughes; David Morrow; Kurt T Randall; Andrea N Selseth; Julia C Ford; Roxanne M Gilbride; Bryan E Randall; Emily Ainslie; Kelli Oswald; Rebecca Shoemaker; Randy Fast; William J Bosche; Michael K Axthelm; Yoshinori Fukazawa; George N Pavlakis; Barbara K Felber; Slim Fourati; Rafick-Pierre Sekaly; Jeffrey D Lifson; Jan Komorowski; Ewelina Kosmider; Danica Shao; Wenjun Song; Paul T Edlefsen; Louis J Picker; Michael Gale
Journal:  PLoS Pathog       Date:  2021-07-06       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.